Ya Feng1 
,
Weichun Liang2,
Wei Liang3,
Xiang Xiao1,
Yalan Zhang1
1Department of Nephrology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China;
2Beijing Huashi Kangyuan Pharmaceutical Technology Co., Ltd., Beijing, China;
3Changchun University of Chinese Medicine, Changchun, China.
For correspondence:- Ya Feng
Email: shaojiure33927318@163.com
Accepted: 31 December 2021
Published: 31 January 2022
Citation:
Feng Y, Liang W, Liang W, Xiao X, Zhang Y.
Effects of XueZhiTong capsules on chronic kidney disease patients with dyslipidemia. Trop J Pharm Res 2022; 21(1):177-183
doi:
10.4314/tjpr.v21i1.26
© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Abstract
Purpose: To determine the clinical effectiveness of Xuezhitong capsule in chronic kidney disease (CKD) patients with dyslipidemia, and its influence on inflammation and oxidative stress.
Methods: Ninety CKD patients with dyslipidemia who were admitted to the Department of Nephrology of our hospital from January 2018 to January 2020 were randomly assigned to group A (treated with Xuezhitong capsules), group B (treated with combination of Xuezhitong capsules and atorvastatin), and group C (treated with atorvastatin), with 30 cases in each group. Renal function, lipid indicators, inflammatory indicators, and degree of oxidative stress were compared among the three groups of patients after 3 consecutive months of treatment.
Results: At 3 months after treatment, estimated glomerular filtration rate (eGFR) and urinary albumin creatinine ratio (UACR) were markedly decreased in all three groups (p < 0.05). After treatment, the levels of TC, TGs, and LDL-C were decreased markedly and time-dependently in the three groups, with the lowest levels in group B, while HDL-C level was elevated with treatment time, with the highest level in group B (p < 0.05). After treatment, the 3 groups exhibited significant decreases in levels of hypersensitive C-reactive protein (hs-CRP), homocysteine (Hcy), and malondialdehyde (MDA), with the lowest levels in group B (p < 0.05). Adiponectin level was significantly increased in each of the 3 groups (p < 0.05).
Conclusion: Xuezhitong capsules exerted lipid-lowering effect and mitigated inflammation and oxidative stress in CKD patients with dyslipidemia, without any adverse effects. This finding provides a new treatment option for elderly CKD patients with dyslipidemia.
Keywords: Chronic kidney disease, Dyslipidemia, Atorvastatin, XueZhiTong capsule, Allium macrostemon
Fulltext in PDF
